Sensei Biotherapeutics’ Future Hinges on Upcoming Clinical Data Release

Clinical-stage biotech firm Sensei Biotherapeutics has scheduled a pivotal virtual event for October 20, 2025, where key opinion leaders will examine comprehensive data for its lead drug candidate, Solnerstotug. The full dose-expansion dataset, which is central to evaluating the therapy’s efficacy and safety profile in treating PD-(L)1-resistant tumors, will be presented just days prior at the European Society for Medical Oncology congress on October 17, 2025.

Solnerstotug is designed as a conditionally active antibody that specifically targets the VISTA checkpoint within the tumor microenvironment, with the goal of reactivating the immune system’s ability to fight cancer. Initial results from the Phase 1/2 study have already demonstrated encouraging activity. In evaluable patients with PD-(L)1-resistant “hot” tumors, an overall response rate of 14% was observed. This figure is nearly triple... Read more...